BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 21628411)

  • 1. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
    Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
    Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
    Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
    Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
    Chen LS; Redkar S; Bearss D; Wierda WG; Gandhi V
    Blood; 2009 Nov; 114(19):4150-7. PubMed ID: 19734450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
    Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIM kinases as therapeutic targets against advanced melanoma.
    Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A
    Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent Inhibition of Pim and FLT3 Kinases Enhances Apoptosis of FLT3-ITD Acute Myeloid Leukemia Cells through Increased Mcl-1 Proteasomal Degradation.
    Kapoor S; Natarajan K; Baldwin PR; Doshi KA; Lapidus RG; Mathias TJ; Scarpa M; Trotta R; Davila E; Kraus M; Huszar D; Tron AE; Perrotti D; Baer MR
    Clin Cancer Res; 2018 Jan; 24(1):234-247. PubMed ID: 29074603
    [No Abstract]   [Full Text] [Related]  

  • 8. Protein kinase C alpha-mediated phosphorylation of PIM-1L promotes the survival and proliferation of acute myeloid leukemia cells.
    Takami M; Katayama K; Noguchi K; Sugimoto Y
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1364-1371. PubMed ID: 30017192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studying c-Myc serine 62 phosphorylation in leukemia cells: concern over antibody cross-reactivity.
    Tibbitts DC; Escamilla-Powers JR; Zhang X; Sears RC
    Blood; 2012 May; 119(22):5334-5. PubMed ID: 22653959
    [No Abstract]   [Full Text] [Related]  

  • 10. Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program.
    Batra V; Maris JM; Kang MH; Reynolds CP; Houghton PJ; Alexander D; Kolb EA; Gorlick R; Keir ST; Carol H; Lock R; Billups CA; Smith MA
    Pediatr Blood Cancer; 2012 Oct; 59(4):749-52. PubMed ID: 22052829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells.
    Hospital MA; Green AS; Lacombe C; Mayeux P; Bouscary D; Tamburini J
    Blood; 2012 Feb; 119(7):1791-2. PubMed ID: 22343664
    [No Abstract]   [Full Text] [Related]  

  • 12. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms.
    Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR
    Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
    Keeton EK; McEachern K; Dillman KS; Palakurthi S; Cao Y; Grondine MR; Kaur S; Wang S; Chen Y; Wu A; Shen M; Gibbons FD; Lamb ML; Zheng X; Stone RM; Deangelo DJ; Platanias LC; Dakin LA; Chen H; Lyne PD; Huszar D
    Blood; 2014 Feb; 123(6):905-13. PubMed ID: 24363397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
    Lee JK; Chatterjee A; Scarpa M; Bailey CM; Niyongere S; Singh P; Mustafa Ali MK; Kapoor S; Wang Y; Silvestri G; Baer MR
    Cancer Res Commun; 2024 Feb; 4(2):431-445. PubMed ID: 38284896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
    Chen LS; Yang JY; Liang H; Cortes JE; Gandhi V
    Leuk Lymphoma; 2016 Dec; 57(12):2863-2873. PubMed ID: 27054578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and activities of new indolopyrrolobenzodiazepine derivatives toward acute myeloid leukemia cells.
    Giraud F; Bourhis M; Ebrahimi E; Herfindal L; Choudhury RR; Bjørnstad R; Døskeland SO; Anizon F; Moreau P
    Bioorg Med Chem; 2015 Nov; 23(22):7313-23. PubMed ID: 26526744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
    Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST
    Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.
    Meja K; Stengel C; Sellar R; Huszar D; Davies BR; Gale RE; Linch DC; Khwaja A
    Br J Haematol; 2014 Oct; 167(1):69-79. PubMed ID: 24975213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
    Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS
    Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel anti-adipogenic effect and mechanisms of action of SGI-1776, a Pim-specific inhibitor, in 3T3-L1 adipocytes.
    Park YK; Hong VS; Lee TY; Lee J; Choi JS; Park DS; Park GY; Jang BC
    Int J Mol Med; 2016 Jan; 37(1):157-64. PubMed ID: 26719859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.